UY37498A - Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma - Google Patents

Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma

Info

Publication number
UY37498A
UY37498A UY0001037498A UY37498A UY37498A UY 37498 A UY37498 A UY 37498A UY 0001037498 A UY0001037498 A UY 0001037498A UY 37498 A UY37498 A UY 37498A UY 37498 A UY37498 A UY 37498A
Authority
UY
Uruguay
Prior art keywords
methyl
pharmaceutical formulations
acetamide
aminosulfonil
piridinyl
Prior art date
Application number
UY0001037498A
Other languages
English (en)
Inventor
Yogeshwar Bachhav Dr
Susanne Bonsmann
Wilfried Schwab Dr
Alexander Birkmann Dr
Thomas Goldner Dr
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Publication of UY37498A publication Critical patent/UY37498A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo de los agentes antivirales activos, particularmente a sales, más particularmente a una sal maleato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, a sus formulaciones farmacéuticas así como a métodos para la producción de estas sales. La presente invención también se refiere al uso de estas sales y de sus formulaciones farmacéuticas respectivas en métodos de tratamiento y/o prevención de infecciones con el virus herpes simple humano, particularmente infecciones causadas por HSV-1 y HSV-2.
UY0001037498A 2016-11-28 2017-11-28 Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma UY37498A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16201009 2016-11-28

Publications (1)

Publication Number Publication Date
UY37498A true UY37498A (es) 2018-06-29

Family

ID=57421722

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037498A UY37498A (es) 2016-11-28 2017-11-28 Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma

Country Status (14)

Country Link
US (2) US11266636B2 (es)
EP (2) EP3892620A1 (es)
JP (2) JP7316214B2 (es)
CN (3) CN117186085A (es)
AR (1) AR110251A1 (es)
AU (4) AU2017365639B2 (es)
CA (1) CA3045063A1 (es)
ES (1) ES2877854T3 (es)
HU (1) HUE054845T2 (es)
PL (1) PL3544977T3 (es)
PT (1) PT3544977T (es)
TW (3) TWI753972B (es)
UY (1) UY37498A (es)
WO (1) WO2018096177A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
AR110249A1 (es) * 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
CN117186085A (zh) * 2016-11-28 2023-12-08 艾库里斯有限及两合公司 普瑞利韦硫酸盐、其药物制剂、制造方法及治疗疱疹病毒的用途
WO2019068817A1 (en) 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6944877B1 (en) * 1999-08-27 2005-09-13 Koninklijke Philips Electronics N.V. Closed loop addressable advertising system and method of operation
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
WO2008004796A1 (en) * 2006-07-03 2008-01-10 Sk Chemicals Co., Ltd. Salts of pyrrolopyrimidinone derivatives and process for preparing the same
WO2011115173A1 (ja) * 2010-03-18 2011-09-22 興和株式会社 ベンゾチアジン化合物のモノマレイン酸塩
EP2598502B1 (en) 2011-09-26 2014-05-14 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations.
EP2573086A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
SG11201506153TA (en) * 2013-02-12 2015-09-29 Aicuris Gmbh & Co Kg Helicase-primase inhibitors for use in a method of treating alzheimer's disease
AR110249A1 (es) * 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
CN117186085A (zh) * 2016-11-28 2023-12-08 艾库里斯有限及两合公司 普瑞利韦硫酸盐、其药物制剂、制造方法及治疗疱疹病毒的用途

Also Published As

Publication number Publication date
AU2021202942B2 (en) 2022-02-17
JP7316214B2 (ja) 2023-07-27
TWI753972B (zh) 2022-02-01
AU2022200409A1 (en) 2022-02-17
TWI808591B (zh) 2023-07-11
TW201825482A (zh) 2018-07-16
EP3544977B1 (en) 2021-05-19
AU2023200773B2 (en) 2024-02-15
CA3045063A1 (en) 2018-05-31
US20200289485A1 (en) 2020-09-17
AU2017365639B2 (en) 2021-03-04
TW202413354A (zh) 2024-04-01
CN117186085A (zh) 2023-12-08
WO2018096177A1 (en) 2018-05-31
AU2021202942A1 (en) 2021-06-03
AR110251A1 (es) 2019-03-13
CN110062755A (zh) 2019-07-26
AU2023200773A1 (en) 2023-03-09
EP3892620A1 (en) 2021-10-13
US11266636B2 (en) 2022-03-08
JP2022145700A (ja) 2022-10-04
PL3544977T3 (pl) 2021-11-08
US20220152009A1 (en) 2022-05-19
AU2017365639A1 (en) 2019-06-06
JP2019535780A (ja) 2019-12-12
CN110062755B (zh) 2023-08-29
TW202231638A (zh) 2022-08-16
CN117186084A (zh) 2023-12-08
PT3544977T (pt) 2021-06-23
AU2022200409B2 (en) 2023-03-02
HUE054845T2 (hu) 2021-10-28
ES2877854T3 (es) 2021-11-17
EP3544977A1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
UY37498A (es) Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
UY37496A (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
CR20160036A (es) Inhibidores cristalinos de bromodominios
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
AR103680A1 (es) Inhibidores selectivos de bace1
CL2014000149A1 (es) Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex.
DOP2014000081A (es) Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
CL2017001001A1 (es) Derivados de carbazaol
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CL2018002811A1 (es) Derivados de aminotiazol útiles como agentes antivíricos.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas